Introduction
The second-generation antipsychotics (SGAs) have established a prominent role in the treatment of schizophrenia due to better treatment adherence and a lower risk of extrapyramidal side effects. 1 On the other hand, SGAs also have side effects that have major impact on compliance, such as sedation, weight gain, anticholinergic effects, sexual dysfunction, and metabolic syndrome. 2 The high attrition rates due to side effects in randomized controlled trials (RCTs) and ''practical trials'' in chronic schizophrenia patients indicate that there are limitations to the use of SGAs in daily practice, despite their efficacy. 3 Therefore, head-to-head comparisons between antipsychotics are necessary to answer the question which antipsychotic drug has the best benefit/risk ratio. 4 In the present study, we compared the effects of 2 SGAs: olanzapine and ziprasidone. Olanzapine has a profile of good efficacy but with a risk of considerable weight gain. 5 In the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial, olanzapine and other SGAs were compared with perphenazine in 1493 chronic schizophrenia patients. The results of the CATIE trial suggest that olanzapine is superior to other antipsychotics in terms of treatment adherence and improvement of psychopathology. 6 Ziprasidone is a relatively new antipsychotic drug that has shown to have comparable efficacy in comparison to conventional antipsychotics. greater improvement in psychopathology and a higher response and completion rate for olanzapine, whereas ziprasidone had a better profile for lipid profiles and weight gain. In contrast, Simpson et al 9, 10 did not detect differences in efficacy but did find a favorable metabolic profile for ziprasidone, including less weight gain and lower fasting insulin, triglycerides, and cholesterol. In the CATIE study, the time to discontinuing treatment was longer for olanzapine than for ziprasidone (P = .028 but not significant because of correction for multiple comparisons), whereas the improvement in psychopathology was similar for both antipsychotics. Ziprasidone had higher rates of insomnia, while olanzapine had more metabolic effects and greater weight gain. 3 Recently, the results of the European First Episode Schizophrenia Trial (EUFEST) study, an open RCT of SGAs vs haloperidol in 498 patients with schizophrenia, were published. In the EUFEST study, ziprasidone and olanzapine showed a comparable treatment discontinuation, but there was more weight gain in the olanzapine group and higher levels of akathisia in the ziprasidone group.
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In addition, 2 studies were published with a crossover design. A significant improvement was found in an openlabel study when stable patients on olanzapine were switched to ziprasidone. 12 The follow-up results of the CATIE study indicate, on the contrary, that among patients who had discontinued another atypical antipsychotic, switching to olanzapine was more effective than switching to ziprasidone. Metabolic effects and weight gain favored ziprasidone, but ziprasidone had more serious adverse events and higher levels of insomnia. 13 It is important to underline that all these comparative studies, except for the EUFEST study, included mostly patients in the chronic stages of the illness. Previous research suggests that first-episode patients respond better to treatment and are more susceptible to side effects such as dystonia and prolactin increase.
14 So far, it is unknown whether this holds true for the drug-induced metabolic syndrome as well. As schizophrenia is often a progressive disorder, it is important for clinicians to know which antipsychotic can reduce the symptoms at an earlier stage. Few trials have addressed this question yet. 15 Furthermore, there are 2 methodological complications of studying patients with chronic schizophrenia. First, previous use of antipsychotics, comorbidity, or ageing may confound outcome variables such as metabolic effects. Second, there is potential study entry bias in chronic patients, favoring the inclusion of more severe, hospitalized patients who are nonresponsive or noncompliant. The higher response rates in first-episode patients are in accordance with this observation. 16 The aim of the present study was to compare the clinical efficacy and side effects of ziprasidone and olanzapine in patients with recent-onset schizophrenia.
Methods

Patients: Inclusion and Exclusion Criteria
Male or female patients, 18-40 years of age, were recruited from 4 academic and nonacademic hospitals in The Netherlands and Belgium. The large majority of the included subjects were acutely ill inpatients. All patients gave written informed consent before screening took place. A diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder was confirmed in Structured Clinical Interviews for Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV). Patients were included if the maximum lifetime exposure to antipsychotics was <16 weeks, duration of illness was <5 years, and Clinical Global Impression Severity (CGI-S) score was !4 (ie, at least ''moderately ill'').
Patients were excluded if they had a DSM-IV diagnosis of substance dependency 3 months prior to screening or a positive drug screen for amphetamines, cocaine, or opioids at screening. Furthermore, patients were excluded if they had epilepsy, an organic mental disease (including mental retardation), a history of psychosurgery or any significant medical illness, abnormal laboratory values, electroencephalogram (ECG) abnormalities (including heartrate-corrected QT-interval [QTc] !500 msec), or medication that prolongs the QT interval. Women who were pregnant, breast-feeding, or not using reliable contraceptive methods were excluded as well. Concurrent treatment with psychopharmacological agents was not allowed, whereas washout periods were permitted depending on the type of pharmacological agent (antidepressants: !7 d, monoamine oxidase inhibitors: !2 wk, fluoxetine: !5 wk, oral antipsychotics: !12 h, depot agents: one cycle [at least 2 wk]). There were no further guidelines for tapering off the previous medication. Patients who were deemed unlikely to follow the study protocol and those at immediate risk of harming themselves or others were excluded as well. Previous treatment with 1 of the 2 study drugs (eg, nonresponding) did not serve as an exclusion criterion.
Study Design
The study was an 8-week, double-blind, parallel-group, randomized, controlled multicenter trial (NCT00145444). Effects on cognitive measures will be published elsewhere (N. van Veelen, K.P. Grootens, M.M. Sitskoorn, J. Peuskens, B.G.C. Sabbe, R.J. Verke, R.S. Kahn, in preparation). Patients who completed the 8-week study were offered to continue or to cross over to different medication. The results of this second phase are beyond the scope of the present article and will be described in another article. The study protocol was approved by the local ethical committee and was carried out in accordance with the Declaration of Helsinki.
Following the screening period of <10 days, patients were tapered off their psychotropic treatment. Patients were randomized to 1 of the 2 treatment groups in the ratio Ziprasidone Vs Olanzapine 1:1, receiving a fixed dose for the first 2 days of either ziprasidone 40 mg twice a day or olanzapine 10 mg/d. From day 3 onward, the dose regimen was flexible and consisted of 3 doses (''low,'' ''medium,'' and ''high'': ziprasidone 40, 60, or 80 mg twice a day or olanzapine 10, 15, or 20 mg/d respectively). The medication was dispensed in a double dummy design to keep the allocation double blinded.
Patients were assessed on day 1, day 3, week 1, week 2, week 4, and week 8 and in between if necessary due to adverse events. In case of akathisia, propranolol was permitted. In patients receiving stable doses of anticholinergic agents prior to randomization, the anticholinergic agents were withdrawn a week after randomization. If sedation was necessary, temazepam or oxazepam up to 20 mg/d was permitted. Any concomitant drug treatment remained constant during the study, and no such drug was started during the study unless considered medically necessary (ie, antidepressants for comorbid depression).
The sample size was determined on the base of the California Verbal Learning Test, the primary cognitive outcome measure: Using a 2-sided test, a sample size of approximately 37 patients per treatment group would assure 80% power to detect a difference of at least 1.6 points in change (a = .05) assuming an SD of 2.4 (according to interim results at wk 6 from studies R-0554 and R-0555, data on file). 17 
Efficacy Assessments
Clinical efficacy was assessed on the basis of a reduction from baseline to week 8 in the total score of the Positive and Negative Syndrome Scale (PANSS), the CGI-S Scale, Clinical Global Impression Improvement (CGI-I) Scale, and the Calgary Depression Scale for Schizophrenia (CDSS). 18 The PANSS was administered at baseline, week 4, and week 8 (or end visit) 19 ; the CGI-S and CGI-I were administered at every visit. The interpersonal relations element of the Heinrich Quality of Life Scale (HQLS) was used to evaluate quality of life at baseline and week 8. 20 In addition to the continuous data, the percentages of patients with clinical response were compared, with response criteria set a priori at 20% reduction in the total PANSS scores. The results from the PANSS were also considered in terms of proposed remission criteria (''mild'' or less on items P1, P2, P3, N1, N4, N6, G5, G9). The criterion ''maintenance over a 6-month period'' could not be applied in the present study. 21 The percentage of patients who fulfilled these remission criteria was calculated as well. 
Safety and Tolerability Measures
All adverse events, regardless of the causal relationship, were monitored and assessed on severity. Vital signs and body weight were checked at baseline, week 4, and week 8. All patients underwent ECG evaluation by a cardiologist at baseline and at week 1. Laboratory safety assessments at baseline and week 8 included cholesterol, triglycerides, fasting glucose, prolactin, and the transaminases serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT). Extrapyramidal side effects were monitored with the St Hans Rating Scale (SHRS), 22 Barnes Akathisia Scale (BAS), 23 and Abnormal Involuntary Movement Scale (AIMS). 24 All participating researchers were trained in the administration and scoring of the instruments for efficacy and safety in consensus meetings, with an independent expert and with high interrater reliability.
Where considered necessary by the investigator, biperiden was administered in case of dyskinisia, parkinsonism, or dystonia, whereas propranolol was administered for akathisia. Temazepam and oxazepam were allowed for insomnia or additional sedation.
Patients' Opinion
The Drug Attitude Inventory (DAI)-10 was used to assess patients' opinion on the study treatment (baseline, wk 4, and wk 8). 25 
Discontinuation
Primary reasons for early discontinuation were recorded. The compliance was checked every visit by counting the unused blisters. Patients unable to adequately comply with medication (compliance <80% or >120% since the previous study visit) were withdrawn from the study. Patients with marked liver function abnormalities were immediately withdrawn from the study (SGOT/SGPT ! 3 3 upper limit of the norms, alkaline phosphates ! 1.5 3 upper limit, total bilirubin ! 2 3 upper limit). The difference between the 2 antipsychotics in treatment discontinuation was tested with a Kaplan-Meier analysis.
Statistical Analysis
The description of demographic data and the description and analyses of safety data were based on all subjects who were randomized and who were known to have taken at least one dose of study medication. The analyses of efficacy and effectiveness data were based on the intention-totreat population with the last observation carried forward.
For continuous data outcome measures, an analysis of covariance (ANCOVA) model was used to test the effect of treatment at week 8 vs baseline. Dependent measures in the ANCOVA analyses were the PANSS total score (primary outcome measure) and subscores, CDSS, CGI, and QLS. The subject's score at baseline included a covariate in order to control for the initial value. ''Treatment center'' was set as an extra independent variable. Analyses of CGI-I scores did not include baseline terms because a baseline CGI-I score could not be determined.
As with the efficacy analysis, ANCOVA was used with treatment center as the factor and baseline levels as covariates. An additional baseline-to-maximum analysis was performed for the side effect scales BAS, AIMS, and SHRS. In order to gain more insight into the clinical consequences of the study intervention, we performed additional analyses on proportions of patients with clinically significant abnormalities based on international consensus, eg, 7% weight increase. For dichotomous data, Fisher exact tests were used.
All statistical tests were 2 tailed (superiority design), with a 5% level of significance. SPSS 14.0 was used for the statistical analysis.
Results
Characteristics and Disposition of Patients
A total of 81 patients were screened for eligibility, of whom 74 were randomized to either the ziprasidone arm (n = 39) or the olanzapine arm (n = 35) (figure 1). There were no significant differences in the baseline characteristics between the 2 groups (tables 1 and 2). Seven of the patients in the ziprasidone group and 8 patients in the olanzapine group were exposed to olanzapine before. None of the patients were exposed to ziprasidone before. The mean study dose was 14 mg for olanzapine and 104 mg for ziprasidone. During the first 8 weeks of treatment, 11 out of 39 patients in the ziprasidone arm and 6 out of 34 in the olanzapine arm discontinued the study; this difference was not statistically significant (Fisher exact test, P = .28). The Kaplan-Meier analysis for treatment discontinuation in time revealed no significant difference either (P = .22).
Efficacy
Changes in efficacy measures are listed in table 3. Patients from both groups had a similar decrease in PANSS score, the primary outcome measure, compared with baseline (P = .68) (table 4). The percentage of patients showing a clinical response (ie, !20% improvement on the PANSS) was 61% for olanzapine and 60% for ziprasidone (P = 1.00). Thirty-five percent of the olanzapine patients and 40% of the ziprasidone patients fulfilled the remission criteria (P = .80). Group differences on depression symptoms (CDSS), quality of life (HQLS), and clinical impression (CGI) were also nonsignificant.
Safety and Tolerability
The percentages of patients who reported adverse events and required concomitant drugs are shown in table 4.
Treatment with olanzapine was associated significantly more often with weight gain and increased appetite. Treatment with ziprasidone led to more frequent use of biperiden as comedication and more frequent use of antidepressants and propranolol.
Metabolic Side Effects. The analyses revealed significant differences between the 2 study groups in terms of metabolic risk (figure 2). Olanzapine patients had a mean weight increase of 6.8 kg, whereas ziprasidone patients only had an increase of 0.1 kg (P < .001). Additional analyses showed that 64.5% of the olanzapine patients had a weight gain of more than 7%, while this occurred in 3.3% of the ziprasidone group (P < .001). Treatment with olanzapine was associated with an increase in levels of cholesterol, triglycerides, and liver transaminases, whereas treatment with ziprasidone led to lower levels of cholesterol, triglycerides, and liver transaminases (P values < .001) (table 6). There were no group differences in fasting glucose and glycosylated hemoglobin (Hb1ac). Movement Disorders. There were no differences between the 2 groups in any of the extrapyramidal side effect scales (table 5) . Additional analyses comparing the proportion of patients with clinically significant values (!''moderate'' on one of the SHRS items) revealed no significant differences either (5 patients in each group). However, significantly more patients in the ziprasidone group used as needed biperiden to relieve extrapyramidal symptoms (EPSs, table 4).
Sexual Dysfunction. As shown in table 5, there were no differences in the UKU Scale for sexual side effects. In both groups, there were 8 patients with at least one moderate score on one of the items. As a substantial proportion of the patients were on antipsychotics before the study entry, there was a decrease in prolactin levels that was similar in both groups. Nevertheless, 60% and 40% of patients on olanzapine and ziprasidone, respectively, met the criteria for hyperprolactinemia at end point (figure 2).
Cardiac Side Effects. There were no ECG abnormalities in any of the patients. Group differences in QTc were not statistically different.
Patient's Opinion
The results of the DAI-10 indicate that there was no significant difference in the patients' opinion regarding their medication (table 3) .
Discussion
This study is the first head-to-head, double-blind comparison of olanzapine and ziprasidone in patients with recent-onset schizophrenia. The results suggest that both agents have comparable clinical efficacy but show differences in the side effects profile. About two-thirds of the patients in both groups met the response criteria, defined as !20% improvement on the PANSS, and one-third fulfilled remission criteria defined by Andreasen et al. 21 The high response rates in our study are consistent with the literature on recent-onset schizophrenia. 11 The attrition rates did not differ significantly between the 2 groups, but numerically there were more completers on olanzapine. Effects on the depression and quality-of-life scales were marginal in both groups, which may be explained by the low baseline values and the short period of treatment.
We realize that we have included a relatively small number of patients in this study. However, the differences between the 2 patient groups in the primary outcome measure, the difference score on the total PANSS score, are extremely small (effect size d = 0.10, P = .82). A sample of more than 3000 patients would have been required to find this small effect significant at the .05 level. We conclude that the primary results are not biased by insufficient statistical power. Several secondary outcome measures, such as the DAI-10 and the dropout rate, may be prone to type II error. The present difference in dropout rate would have been statistically significant at the 0.05 level if we had included at least 590 patients in our study. The weight gain findings in the olanzapine group are consistent with the literature. 26 However, the mean increase of 6.8 kg we found in the olanzapine group is high in comparison with other studies. The relatively high mean dose of 14 mg olanzapine may have contributed to the higher weight gain. The recent onset of the symptoms and the limited history of antipsychotics in our patient population may explain the difference with previous data as well. This study showed that half of the olanzapine patients had laboratory abnormalities within 8 weeks, whereas this proportion was lower with ziprasidone treatment. This pattern has been previously described in chronic patients as well. 27 We also found a differential effect on transaminases; to our knowledge, this is the first recent-onset study reporting effects on liver enzymes. The increase in transaminases seen with olanzapine may be a transient effect, but it would be worthwhile exploring its clinical implications in future studies. This holds for the increase in prolactin levels as well, although it should be noted that the blood samples were taken in the morning (levels are relatively high at that time of the day). Significantly more anticholinerigc drugs were administered for EPSs in patients treated with ziprasidone. This concomitant medication appeared to relieve the symptoms as there were no differences in the number of patients with clinically manifest EPS. However, longterm biperiden use may result in other problems, such as lower cognitive function. 28 The prescription of other concomitant drugs in both groups did not differ significantly. Although there were more prescriptions of antidepressants in the ziprasidone group, this did not reach statistical significance. Nonetheless, this deserves further attention because the association between depression and ziprasidone has been made previously. 29 It is important to underline that our study population had a recent onset of the syndrome. In this way, there is a smaller chance of a patient selection bias, ie, including subpopulations of severe, untreatable patients. Moreover, studies with recent-onset schizophrenia populations offer the opportunity to examine the effectiveness without the confounding effects of long-term medication use. 4 Recently, metabolic syndrome has been the focus of considerable attention. Unfortunately, we were not able to determine the prevalence of metabolic syndrome in our sample because we did not evaluate waist circumference, low-density lipoprotein, and high-density lipoprotein. The metabolic syndrome is considered a constellation of cardiovascular risk factors linked by insulin resistance, which include obesity, dyslipidemia, glucose tolerance, and hypertension. Antipsychotics, especially those from the second generation, increase the risk of cardiovascular incidents inschizophrenia. Thisrisk is already higher inthis population due to heavy smoking, low treatment adherence for somatic medication, less access to medical care, and a (genetic) higher prevalence of diabetes. It is estimated that patients with schizophrenia have a 20% reduced life expectancy compared with the general population and that two-thirds of schizophrenia patients die of cardiovascular incidents. 30 Taken together, ziprasidone and olanzapine have comparable efficacy, resulting in remission rates of around 40% within 8 weeks. This study further demonstrates that abnormalities of metabolic parameters, which are risk factors for developing metabolic syndrome in the long term, can be detected in substantial proportions of recent-onset schizophrenia patients at an early stage of treatment.
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